Redsense Medical aktie (REDS) | Pressmeddelande

Redsense Medical to focus on core growth areas, discontinuing trading on OTCQX

Cision • 24 Oct 15:25

Nomination committee appointed for the 2025 Annual General Meeting in Redsense Medical AB

Cision • 16 Oct 16:33

Redsense Medical AB (publ) appoints a new CEO

Cision • 24 Sep 09:00

Member of the board of Redsense Medical AB resigns

Cision • 21 Sep 16:59

Chairman of the board of Redsense Medical AB resigns - Acting chairman of the board appointed

Cision • 16 Sep 08:30

Interim Report Q2 – January – June, 2024 Redsense Medical AB (publ.)

Interim Report Q2 – January – June, 2024 Redsense Medical AB (publ.

Cision • 29 Aug 08:30

Major shareholding notification

Cision • 15 Jul 11:30

Redsense has secured a new order worth MSEK 6.99

Redsense has secured a new order worth MSEK 6.

Cision • 28 Jun 18:06

Major shareholding notification

Cision • 25 Jun 14:36

The Board of Directors in Redsense Medical AB (publ) resolves to carry out a directed share issue of MSEK 7,5.

Cision • 31 May 20:45

The CEO leaves Redsense Medical AB

Cision • 27 May 17:13

Major shareholding notification

Cision • 23 May 09:06

Major shareholding notification

Cision • 22 May 18:01

Redsense Medical presents at Sedermeradagen Stockholm 2024

Cision • 15 May 15:07

Redsense Medical Spotlight presentation at the 61[st] ERA Congress in Stockholm

Cision • 13 May 11:06

Kommuniké från årsstämma i Redsense Medical AB (publ) den 8 maj 2024

Redsense Medical AB (publ) höll under onsdagen den 8 maj 2024 årsstämma varvid följande huvudsakliga beslut fattades.

Cision • 08 May 17:45

Interim Report Q1 – January – March, 2024 Redsense Medical AB (publ.)

Interim Report Q1 – January – March, 2024 Redsense Medical AB (publ.

Cision • 08 May 08:30

Redsense Medical welcomes new investment from ShapeQ to accelerate growth

Cision • 24 Apr 17:45

The Board of Directors in Redsense Medical AB (publ) resolves to carry out a directed share issue of approximately MSEK 9,8.

The Board of Directors in Redsense Medical AB (publ) ("Redsense" or the "Company") announces today that the Company’s Board of Directors, wi...

Cision • 24 Apr 17:01

Redsense Medical attending Home Dialysis Congress in Germany

Cision • 19 Apr 16:24

Uppdatering: Redsense Medical AB (publ) årsredovisning 2023, nu med bilagd årsredovisning i pdf

Cision • 16 Apr 14:07

Redsense Medical AB (publ) årsredovisning 2023

Cision • 16 Apr 09:00

Förtydligande: Redsense Medical AB (publ) upplyser att punkt 13 har omformulerats och att veckodagarna som datumen infaller på har uppdaterats.

Förtydligande: Redsense Medical AB (publ) upplyser att punkt 13 har omformulerats och att veckodagarna som datumen infaller på har uppdatera...

Cision • 15 Apr 14:30

KALLELSE TILL ÅRSSTÄMMA I REDSENSE MEDICAL AB (PUBL)

Cision • 02 Apr 09:00

Home Dialysis Risk Prevention Act addressed in House Committee on Ways and Means Hearing

Cision • 14 Mar 16:30

Redsense Medical presents at Redeye Theme: Commercialization in Life Science

Cision • 13 Mar 10:30

Redsense Medical attending US dialysis conferences this spring

Cision • 08 Mar 10:00

Meet Redsense Medical at the Swiss Nordic Bio 2024

Cision • 01 Mar 10:00

Correction: Missing MAR-lable in previous press release - "Year-End Report – January – December, 2023 Redsense Medical AB (publ)"

Cision • 27 Feb 09:02

Year-End Report – January – December, 2023 Redsense Medical AB (publ)

Cision • 27 Feb 08:30

Redsense Medical presents at Stora AktiedagarnaStockholm

Cision • 23 Feb 08:00

American Association of Kidney Patients supports the Home Dialysis Risk Prevention Act

AAKP Says Medicare Should Prioritize Safety Innovation

Cision • 15 Feb 11:00

Seventh Sense Adventures Holding AB to remain a long term investor in Redsense Medical AB

Cision • 06 Feb 11:02

Appointment of new Chairman of Redsense Medical’s Board of Directors

Cision • 08 Jan 20:01

Redsense Medical’s Chairman of the Board has passed away

Redsense Medical has received the sad news that the Chairman of the Board, Patrik Byhmer, has passed away.

Cision • 23 Dec 2023 18:30

Redsense Medical to present at the Life Science Investor Forum

Cision • 08 Dec 2023 14:00

Interim Report Q3 – January – September, 2023 Redsense Medical AB (publ)

Cision • 09 Nov 2023 08:36

Nomination Committee appointed for the 2024 Annual General Meeting of Redsense Medical AB

Cision • 26 Oct 2023 09:50

Redsense Medical to present at the Small Cap Growth Virtual Investor Conference

Cision • 05 Oct 2023 17:19

Redsense Medical AB’s shares to begin trading at OTCQX on September 29, 2023

Cision • 29 Sep 2023 13:00

Major shareholding notification

Cision • 28 Sep 2023 14:41

Redsense Medical arranged Congressional Briefing to address Venous Needle Dislodgement

Cision • 27 Sep 2023 17:30

Interim Report Q2 – April – June, 2023 Redsense Medical AB (publ)

Cision • 29 Aug 2023 08:30

Redsense secures strong autumn with MSEK 11.2 order

Cision • 15 Aug 2023 07:54

Redsense Medical’s alarm system featured in KFF Health News

Cision • 07 Jul 2023 15:12

Redsense has submitted application for cross-trading at OTCQX Best Market in the US

Cision • 30 Jun 2023 12:00

Redsense to exhibit at the 60th ERA Congress Milan 2023

Cision • 15 May 2023 15:03

Redsense presents at Sedemeradagen Stockholm 2023

Cision • 11 May 2023 14:58

Kommuniké från årsstämma i Redsense Medical AB (publ) den 9 maj 2023

Cision • 09 May 2023 17:17

Interim Report Q1 – January – March, 2023 Redsense Medical AB (publ)

Cision • 09 May 2023 08:30

Home Dialysis Risk Prevention Act introduced by the US House of Representatives

Cision • 08 May 2023 15:01

Förtydligande: Redsense Medical AB (publ) upplyser om att sista anmälningsdag till årsstämman har förlängts till onsdagen den 3 maj 2023.

Cision • 02 May 2023 18:02

Redsense and the FDA held a Pre-Submission Meeting in Preparation for the 510(k) Premarket Submission for the Redsense Clamp

Cision • 28 Apr 2023 08:00

Redsense Medical AB (publ) årsredovisning 2022

Cision • 14 Apr 2023 08:30

KALLELSE TILL ÅRSSTÄMMA I REDSENSE MEDICAL AB (PUBL)

Cision • 04 Apr 2023 08:00

Redsense presents at Stora Aktiedagarna Stockholm

Cision • 03 Mar 2023 12:29

Redsense Medical AB will present at the Life Science Day in Gothenburg on March 8

Cision • 01 Mar 2023 12:38

Year-end Report 2022 Redsense Medical AB (publ)

Cision • 27 Feb 2023 08:30

Top 10 Technology Hazards for 2023 includes Venous Needle Dislodgement

Cision • 26 Jan 2023 14:55

Redsense Medical reinforces the team with a new CFO

Cision • 20 Jan 2023 09:00

Partial delivery of record order

Cision • 03 Jan 2023 16:19

Styrelseledamot avgår på egen begäran

Cision • 08 Dec 2022 12:34

New order valued at 15.2 MSEK smashes previous company record

Cision • 02 Dec 2022 08:40

Correction: Consolidated cash flow analysis interim report January-September 2022 Redsense Medical AB (publ)

Cision • 15 Nov 2022 15:42

Interim Report Q3 – July – September, 2022 Redsense Medical AB (publ)

Cision • 09 Nov 2022 08:30

Valberedning utsedd inför årsstämman 2023 i Redsense Medical AB

Cision • 21 Oct 2022 16:42

Redsense receives highest value order to date

Cision • 18 Oct 2022 14:43

Redsense presents at Aktiedagen Lund

Cision • 16 Sep 2022 11:59

New article brings forward support for home dialysis in connection with comorbidities

Cision • 15 Sep 2022 10:21

Interim Report Q2 – April – June, 2022 Redsense Medical AB (publ)

Cision • 29 Aug 2022 08:45

Redsense announces CEO succession date

Cision • 06 Jul 2022 12:46

Redsense to exhibit on the 59[th] ERA-EDTA congress

Cision • 11 May 2022 11:19

Kommuniké från årsstämma i Redsense Medical AB (publ) den 2 maj 2021

Cision • 02 May 2022 18:38

Redsense announces new CEO

Cision • 02 May 2022 12:50

Interim Report Q1 – January – March, 2022 Redsense Medical AB (publ)

Cision • 02 May 2022 08:30

Redsense Medical AB (publ) årsredovisning 2021

Cision • 06 Apr 2022 11:30

New MHRA Guidance acknowledges the need to monitor for VND

Redsense Medical announces today that the UK Medicines & Healthcare Products Regulatory Agency (MHRA) has issued a new dialysis guidance, in...

Cision • 23 Mar 2022 09:57

Redsense participates in US congress briefing on VND

Cision • 16 Mar 2022 08:01

Redsense Medical and partners winner in standard setting procurement contract in Sweden

Redsense Medical, dialysis machine manufacturer Physidia, and distributor Nordic Medcom make up the winners of a public procurement contract...

Cision • 15 Mar 2022 12:45

Year-end Report 2021 Redsense Medical AB (publ)

Cision • 28 Feb 2022 08:30

Senarelagd publicering av delårsraport

Cision • 18 Feb 2022 15:57

Redsense registered with the MHRA for continued access to the Great Britain market

Cision • 30 Dec 2021 16:00

Patrik Byhmer, nuvarande VD, föreslås som ny styrelseordförande i Redsense Medical

Valberedningen kommer föreslå att Patrik Byhmer, nuvarande VD och tillika bolagets största enskilda ägare, tar över som styrelseordförande p...

Cision • 07 Dec 2021 13:40

Redsense receives order from Christus Spohn Hospital in the United States

Cision • 18 Nov 2021 10:10

Analysguiden: Ljuset i tunneln?

Redsense Medical rapporterade en nettoomsättning om 3,6 miljoner kronor för tredje kvartalet och fick sin första order i Kanada.

Cision • 09 Nov 2021 16:57

Interim Report Q3 – July – September, 2021 Redsense Medical AB (publ)

Cision • 09 Nov 2021 08:30

Valberedning utsedd inför årsstämman 2022 i Redsense Medical AB

Cision • 18 Oct 2021 12:52

Redsense receives first order from Canada

Cision • 13 Oct 2021 11:01

Analysguiden: Vi ser starkt andra halvår

Redsense Medical rapporterade ett kvartal fortsatt negativt påverkat av Covid-19.

Cision • 13 Sep 2021 09:49

BioStock: Redsense Medical ser ljust på framtiden

Halmstadsbaserade Redsense Medical, som utvecklat ett alarmsystem för blodläckage för användning vid dialys, presenterade nyligen sin Q2-rap...

Cision • 03 Sep 2021 08:53

BioStock Studio: Redsense Medicals vd ser återhämtning i USA

Medicinteknikbolaget Redsense Medical publicerade nyligen sin halvårsrapport där man redogör för flera viktiga händelser under perioden.

Cision • 26 Aug 2021 11:41

Interim Report Q2 – April – June, 2021 Redsense Medical AB (publ)

Cision • 24 Aug 2021 08:30

Redsense signs new distributor agreement for Canada and Bermuda with CardioMed Supplies Inc.

Cision • 16 Aug 2021 09:04

BioStock: Redsense Medicals vd sammanfattar första halvåret och blickar framåt

År 2021 har inletts med hög aktivitet för Redsense Medical, som bland annat genomfört en framgångsrik avknoppning av dotterbolaget Odinwell,...

Cision • 15 Jul 2021 09:58

Kommuniké från årsstämma i Redsense Medical AB (publ) den 12 maj 2021

Redsense Medical AB (publ) höll under onsdagen den 12 maj 2021 årsstämma varvid följande huvudsakliga beslut fattades.

Cision • 12 May 2021 14:24

Analysguiden: Pandemityngt första kvartal – långsiktiga caset intakt

Pandemin fortsätter att tynga medicinteknikbolaget Redsense försäljning.

Cision • 07 May 2021 14:55

Interim Report Q1 - January - March, 2021 Redsense Medical AB (publ)

Cision • 03 May 2021 08:30

Uppdatering: Ny fastställd avstämningsdag för utdelning av dotterbolaget Odinwell AB

Cision • 21 Apr 2021 15:04

Redsense Medical AB (publ) årsredovisning 2020

Cision • 21 Apr 2021 08:30

Redsense Medical: Flaggningsmeddelande

Cision • 19 Apr 2021 14:10

Börskollen

För dig med koll på börsen

Pressmeddelanden från Redsense Medical

Redsense Medical to focus on core growth areas, discontinuing trading on OTCQX

Nomination committee appointed for the 2025 Annual General Meeting in Redsense Medical AB

Redsense Medical AB (publ) appoints a new CEO

Member of the board of Redsense Medical AB resigns

Chairman of the board of Redsense Medical AB resigns - Acting chairman of the board appointed

Interim Report Q2 – January – June, 2024 Redsense Medical AB (publ.)

Major shareholding notification

Redsense has secured a new order worth MSEK 6.99

Major shareholding notification

The Board of Directors in Redsense Medical AB (publ) resolves to carry out a directed share issue of MSEK 7,5.

The CEO leaves Redsense Medical AB

Major shareholding notification

Major shareholding notification

Redsense Medical presents at Sedermeradagen Stockholm 2024

Redsense Medical Spotlight presentation at the 61[st] ERA Congress in Stockholm

Kommuniké från årsstämma i Redsense Medical AB (publ) den 8 maj 2024

Interim Report Q1 – January – March, 2024 Redsense Medical AB (publ.)

Redsense Medical welcomes new investment from ShapeQ to accelerate growth

The Board of Directors in Redsense Medical AB (publ) resolves to carry out a directed share issue of approximately MSEK 9,8.

Redsense Medical attending Home Dialysis Congress in Germany

Uppdatering: Redsense Medical AB (publ) årsredovisning 2023, nu med bilagd årsredovisning i pdf

Redsense Medical AB (publ) årsredovisning 2023

Förtydligande: Redsense Medical AB (publ) upplyser att punkt 13 har omformulerats och att veckodagarna som datumen infaller på har uppdaterats.

KALLELSE TILL ÅRSSTÄMMA I REDSENSE MEDICAL AB (PUBL)

Home Dialysis Risk Prevention Act addressed in House Committee on Ways and Means Hearing

Redsense Medical presents at Redeye Theme: Commercialization in Life Science

Redsense Medical attending US dialysis conferences this spring

Meet Redsense Medical at the Swiss Nordic Bio 2024

Correction: Missing MAR-lable in previous press release - "Year-End Report – January – December, 2023 Redsense Medical AB (publ)"

Year-End Report – January – December, 2023 Redsense Medical AB (publ)

Redsense Medical presents at Stora AktiedagarnaStockholm

American Association of Kidney Patients supports the Home Dialysis Risk Prevention Act

Seventh Sense Adventures Holding AB to remain a long term investor in Redsense Medical AB

Appointment of new Chairman of Redsense Medical’s Board of Directors

Redsense Medical’s Chairman of the Board has passed away

Redsense Medical to present at the Life Science Investor Forum

Interim Report Q3 – January – September, 2023 Redsense Medical AB (publ)

Nomination Committee appointed for the 2024 Annual General Meeting of Redsense Medical AB

Redsense Medical to present at the Small Cap Growth Virtual Investor Conference

Redsense Medical AB’s shares to begin trading at OTCQX on September 29, 2023

Major shareholding notification

Redsense Medical arranged Congressional Briefing to address Venous Needle Dislodgement

Interim Report Q2 – April – June, 2023 Redsense Medical AB (publ)

Redsense secures strong autumn with MSEK 11.2 order

Redsense Medical’s alarm system featured in KFF Health News

Redsense has submitted application for cross-trading at OTCQX Best Market in the US

Redsense to exhibit at the 60th ERA Congress Milan 2023

Redsense presents at Sedemeradagen Stockholm 2023

Kommuniké från årsstämma i Redsense Medical AB (publ) den 9 maj 2023

Interim Report Q1 – January – March, 2023 Redsense Medical AB (publ)

Home Dialysis Risk Prevention Act introduced by the US House of Representatives

Förtydligande: Redsense Medical AB (publ) upplyser om att sista anmälningsdag till årsstämman har förlängts till onsdagen den 3 maj 2023.

Redsense and the FDA held a Pre-Submission Meeting in Preparation for the 510(k) Premarket Submission for the Redsense Clamp

Redsense Medical AB (publ) årsredovisning 2022

KALLELSE TILL ÅRSSTÄMMA I REDSENSE MEDICAL AB (PUBL)

Redsense presents at Stora Aktiedagarna Stockholm

Redsense Medical AB will present at the Life Science Day in Gothenburg on March 8

Year-end Report 2022 Redsense Medical AB (publ)

Top 10 Technology Hazards for 2023 includes Venous Needle Dislodgement

Redsense Medical reinforces the team with a new CFO

Partial delivery of record order

Styrelseledamot avgår på egen begäran

New order valued at 15.2 MSEK smashes previous company record

Correction: Consolidated cash flow analysis interim report January-September 2022 Redsense Medical AB (publ)

Interim Report Q3 – July – September, 2022 Redsense Medical AB (publ)

Valberedning utsedd inför årsstämman 2023 i Redsense Medical AB

Redsense receives highest value order to date

Redsense presents at Aktiedagen Lund

New article brings forward support for home dialysis in connection with comorbidities

Interim Report Q2 – April – June, 2022 Redsense Medical AB (publ)

Redsense announces CEO succession date

Redsense to exhibit on the 59[th] ERA-EDTA congress

Kommuniké från årsstämma i Redsense Medical AB (publ) den 2 maj 2021

Redsense announces new CEO

Interim Report Q1 – January – March, 2022 Redsense Medical AB (publ)

Redsense Medical AB (publ) årsredovisning 2021

New MHRA Guidance acknowledges the need to monitor for VND